Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Abeona TherapeuticsABEO | Open-market sale | 09/29 | 09/29 | 9,191 sh | $5.16 | $47,385.12 | −1.9% | |
Abeona TherapeuticsABEO | Open-market sale | 09/29 | 09/29 | 19,608 sh | $5.16 | $101,091 | −1.5% | |
Brendan M. O'MalleySVP, Chief Legal Officer | Abeona TherapeuticsABEO | Open-market sale | 09/29 | 09/29 | 6,727 sh | $5.16 | $34,681.72 | −1.6% |
Madhav VasanthavadaChief Commercial Officer | Abeona TherapeuticsABEO | Open-market sale | 09/29 | 09/29 | 4,902 sh | $5.16 | $25,272.75 | −1.7% |
Christine Berni SilversteinDirector | Abeona TherapeuticsABEO | Open-market sale | 06/15 | 06/15 | 18,160 sh | $5.71 | $103,693.6 | −13.2% |
Abeona TherapeuticsABEO | Open-market sale10b5-1 plan | 06/08–06/09 | 06/09 | 49,338 sh3 trades | $5.37avg. | $265,134.77 | −8.7% | |
Abeona TherapeuticsABEO | Open-market sale | 06/08–06/09 | 06/09 | 56,344 sh2 trades | $5.36avg. | $301,798.84 | −3.9% | |
Abeona TherapeuticsABEO | Open-market sale | 06/08–06/09 | 06/09 | 11,131 sh2 trades | $5.36avg. | $59,621.68 | −2.5% | |
Abeona TherapeuticsABEO | Open-market sale | 06/08–06/09 | 06/09 | 9,620 sh2 trades | $5.36avg. | $51,528.1 | −3.1% | |
Alvino MarkDirector | Abeona TherapeuticsABEO | Open-market sale | 05/22 | 05/22 | 6,500 sh | $5.46 | $35,490 | −7.7% |
Eric CrombezDirector | Abeona TherapeuticsABEO | Open-market sale10b5-1 plan | 05/15 | 05/15 | 26,143 sh | $5.53 | $144,570.79 | −41.2% |
Madhav VasanthavadaChief Commercial Officer | Abeona TherapeuticsABEO | Open-market sale | 05/11 | 05/11 | 5,548 sh | $5.96 | $33,066.08 | −1.7% |
Abeona TherapeuticsABEO | Open-market sale10b5-1 plan | 03/31 | 03/31 | 29,985 sh | $4.38 | $131,334.3 | −2.1% | |
Abeona TherapeuticsABEO | Open-market sale | 03/16 | 03/16 | 785 sh | $4.76 | $3,736.6 | −0.1% | |
Christine Berni SilversteinDirector | Abeona TherapeuticsABEO | Open-market sale | 02/02 | 02/04 | 20,070 sh | $5.09 | $102,156.3 | −12.7% |
Alvino MarkDirector | Abeona TherapeuticsABEO | Open-market sale | 02/02 | 02/02 | 2,000 sh | $5.09 | $10,180 | −2.3% |
Eric CrombezDirector | Abeona TherapeuticsABEO | Open-market sale | 02/02 | 02/02 | 16,284 sh | $5.09 | $82,885.56 | −20.4% |
Leila AllandDirector | Abeona TherapeuticsABEO | Open-market sale | 02/02 | 02/02 | 18,065 sh | $5.09 | $91,950.85 | −9.4% |
Donald A. WuchterlDirector | Abeona TherapeuticsABEO | Open-market sale | 02/02 | 02/02 | 14,814 sh | $5.09 | $75,403.26 | −8.1% |
Madhav VasanthavadaChief Commercial Officer | Abeona TherapeuticsABEO | Open-market sale | 01/22 | 01/26 | 12,610 sh | $5.29 | $66,706.9 | −3.8% |